StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.70+0.80 (+5.03%)

Close on Nov 17, 2026Market cap $1.65BP/E –Yield –

Ultragenyx Pharmaceutical gross margin

Gross margin is gross profit as a percentage of revenue.

Ultragenyx Pharmaceutical's gross margin for the twelve months ending Jun 30, 2019 was 97.2%. For fiscal 2018 it was 97.8%, against 100.0% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2018Dec 31, 201897.8%−2.2
FY2017Dec 31, 2017100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2019Jun 30, 201996.8%−2.1
Q1 FY2019Mar 31, 201997.5%−0.4
Q4 FY2018Dec 31, 201896.9%–
Q3 FY2018Sep 30, 201897.7%–
Q2 FY2018Jun 30, 201898.9%–
Q1 FY2018Mar 31, 201897.9%–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?